Ipatasertib plus abiraterone and prednisone delays progression in mCRPC with PTEN loss
June 19th 2020Phase 3 data showed that the addition of the AKT inhibitor ipatasertib to standard therapy boosted radiographic progression-free survival in patients with advanced castration-resistant prostate cancer whose tumors had PTEN loss.
Neoadjuvant pembrolizumab regimen impresses in locally advanced urothelial cancer
June 17th 2020Neoadjuvant pembrolizumab plus chemotherapy achieved a high rate of pathologic downstaging to noninvasive disease and was associated with a high radical cystectomy rate in cisplatin-eligible patients with urothelial cancer.